 The purpose of this study is to demonstrate the efficacy and safety of omalizumab, compared with placebo, as an add-on to H1AH therapy in adult patients suffering from CSU who remain symptomatic despite H1AH therapy. The results of this study will support registration of omalizumab for adult patients suffering from CSU in China, and potentially in other countries. 